Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asacol Dosing Frequency for Induction of Remission in Ulcerative Colitis
NCT00194818Phase 4Completed
- Sponsor
- University of Washington
- Start
- Jun 2003
- Primary completion
- Aug 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Salcrozine in ulcerative colitis (UC) (2 arms), sponsored by University of Washington. Primary endpoint: Proportion of patients with clinical remission at 12 weeks. Started Jun 2003; status: completed.
02
Drugs
Salcrozine
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT00194818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00194818.